What is the IDEAL trial studying for Oryzon Genomics?

IDEAL is a multicentre, single-arm Phase II study evaluating the safety, tolerability and clinical activity of iadademstat in adults with ET who are resistant or intolerant to hydroxyurea. The study will include assessment of its efficacy in reducing the percentage of adult ET patients with abnormal platelet counts.

Where is Oryzon Genomics conducting the IDEAL trial?

Oryzon Genomics is conducting the IDEAL trial in Spain across multiple centres. It is enrolling adult patients with essential thrombocythemia who are resistant or intolerant to hydroxyurea.

How long will patients receive iadademstat in Oryzon Genomics’ IDEAL trial?

Iadademstat will be administered for up to 24 weeks in the IDEAL trial. An additional 24-week extension period is available for patients benefiting from treatment.

What outcomes will Oryzon Genomics assess in the IDEAL trial?

The IDEAL trial is designed to assess the safety, tolerability and clinical activity of iadademstat, including effects on platelet counts and haematologic responses. Oryzon Genomics’ Senior Vice-President of Clinical Development and Global Medical Affairs, Dr Ana Limón, said the study will also further characterise the biological impact of LSD1 inhibition in essential thrombocythemia.

What did Oryzon Genomics say about the need for new essential thrombocythemia treatments?

Oryzon Genomics said that essential thrombocythemia is characterised by persistently elevated platelet counts and an increased risk of thrombotic complications. The company also said that a significant proportion of patients become resistant or intolerant to first-line treatments such as hydroxyurea, despite available therapies.

How does Oryzon Genomics describe iadademstat’s wider development programme?

Oryzon Genomics said iadademstat is being developed across haematologic malignancies, solid tumours and non-malignant haematology. Additional trials are in progress under a Cooperative Research and Development Agreement with the U.S. National Cancer Institute and as investigator-sponsored studies in myeloproliferative neoplasms, myelodysplastic syndrome and small cell lung cancer.

What did Oryzon Genomics report from the ALICE-2 study?

Oryzon Genomics reported that updated ALICE-2 data showed a 100% overall response rate (ORR), a 93% composite complete remission (CRc) rate and a 79% true complete remission (CR) rate at the abstract submission cut-off. The study involved first-line acute myeloid leukaemia patients treated with iadademstat, azacitidine and venetoclax.

What did Oryzon Genomics report from the FRIDA study?

Oryzon Genomics said updated clinical data from FRIDA showed a favourable safety profile and a 67% CRc rate in a heavily pre-treated patient population. FRIDA is evaluating iadademstat in combination with gilteritinib in relapsed or refractory FLT3-mutated acute myeloid leukaemia.

When will Oryzon Genomics present updated ALICE-2 and FRIDA results?

Oryzon Genomics said updated results from both ALICE-2 and FRIDA will be presented at the EHA 2026 Congress next week. Dr Carlos Buesa, Oryzon Genomics’ Chief Executive Officer, said the updated ALICE-2 presentation would include a larger patient cohort.

What other iadademstat study is Oryzon Genomics advancing?

Oryzon Genomics said it is advancing the RESTORE trial evaluating iadademstat in sickle cell disease. The company also said additional trials are in progress in other haematologic and oncological conditions.

What are Oryzon Genomics’ ticker and ISIN details?

Oryzon Genomics identifies itself in the announcement as Oryzon Genomics, S.A., with ISIN Code: ES0167733015 and Ticker: ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon reports first patient enrolled in Phase II IDEAL trial for essential thrombocythemia

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon reports first patient enrolled in Phase II IDEAL trial for essential thrombocythemia

Published Tuesday, 02 June 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Operational update
Published: Tuesday, 02 June 2026
Source announcement: oryzon.com

Key figures
Measure	Figure	Period
Overall response rate (ORR)	100%	at the abstract submission cut-off
Composite complete remission (CRc) rate	93%	at the abstract submission cut-off
True complete remission (CR) rate	79%	at the abstract submission cut-off
CRc rate	67%	Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

On June 2, 2026, Oryzon Genomics, S.A. (Ticker: ORY) announced first-patient enrollment in IDEAL, a Phase II iadademstat study for essential thrombocythemia.

IDEAL is a multicenter, single-arm Phase II study being conducted in Spain for adults with essential thrombocythemia.
Eligible patients are resistant or intolerant to hydroxyurea.
The study evaluates safety, tolerability and clinical activity, including efficacy in reducing abnormal platelet counts.
Iadademstat will be administered for up to 24 weeks.
An additional 24-week extension is available for patients benefiting from treatment.

At EHA 2026 next week, Oryzon said it will present updated ALICE-2 and FRIDA results; reported rates included 100% ORR, 93% CRc, 79% CR and 67% CRc.

Investor FAQs

Oryzon Genomics announced that the first patient had been enrolled in IDEAL, its Phase II study evaluating iadademstat in patients with essential thrombocythemia (ET).

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential thrombocythemia
Published: Tuesday, 02 June 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…